What education should be provided to a patient with type 2 diabetes starting tirzepatide (Mounjaro) regarding dosing, injection technique, storage, lifestyle recommendations, potential adverse effects, contraindications, and monitoring?

Tirzepatide (Mounjaro) Patient Education

Patients starting tirzepatide should understand this is a once-weekly subcutaneous injection that will be gradually increased from 2.5 mg to a maximum of 15 mg over several months, with gastrointestinal side effects being common but typically manageable through dietary modifications. 1

Dosing and Administration

Starting dose and titration:

• Begin at 2.5 mg once weekly for 4 weeks
• Increase to 5 mg weekly, then 10 mg, and potentially 15 mg
• Titrate monthly based on tolerance and glycemic response 1

Injection technique:

• Administer subcutaneously once weekly at any time of day, with or without meals
• Inject into abdomen, thigh, or upper arm
• Rotate injection sites with each dose
• Never share pens between patients - risk of blood-borne pathogen transmission 2
• Use a new needle for each injection if using vials 2

Missed doses:

• If missed, take within 4 days of scheduled dose
• If more than 4 days have passed, skip the missed dose and resume regular schedule 2

Storage Requirements

• Store in refrigerator (36-46°F/2-8°C)
• May be kept at room temperature for up to 21 days if needed
• Protect from light
• Do not freeze; discard if frozen 2

Expected Benefits

Glycemic control:

• HbA1c reduction of 1.9-2.2% in patients with type 2 diabetes 1
• Over 87% of patients achieve HbA1c <7% 1

Weight loss:

• Average weight reduction of 12.8-22.5% depending on dose (10-15 mg)
• Superior to GLP-1 receptor agonists alone 3
• 15-20% body weight reduction typical in diabetes patients 3

Common Side Effects and Management

Gastrointestinal symptoms (most common):

• Nausea occurs in approximately 25% of patients 3
• Vomiting and diarrhea in up to 10% 3
• These typically worsen with dose escalation but often improve with time 3

Dietary strategies to minimize GI side effects:

• Eat smaller, more frequent meals
• Stop eating when feeling full - do not overeat
• Drink plenty of water throughout the day
• Increase dietary fiber gradually
• Eat slowly and chew thoroughly
• Avoid high-fat, greasy, or spicy foods
• Moderate alcohol and carbonated beverages 3, 1, 3

Serious Warnings and Contraindications

Absolute contraindications:

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• Previous serious allergic reaction to tirzepatide 2

Contact provider immediately if experiencing:

• Severe abdominal pain with or without nausea/vomiting (possible pancreatitis - stop medication immediately) 3
• Persistent nausea, vomiting, or diarrhea leading to dehydration 2
• Signs of gallbladder disease (right upper abdominal pain, fever, jaundice) 3
• Lump or swelling in neck, hoarseness, difficulty swallowing, or shortness of breath (thyroid concerns) 2
• Changes in vision (especially if history of diabetic retinopathy) 2
• Signs of kidney problems (decreased urination, swelling, confusion) 2

Special Precautions

Pregnancy and contraception:

• Discontinue tirzepatide at least 2 months before planned pregnancy
• Oral contraceptives may be less effective - switch to non-oral method or add barrier method for 4 weeks after starting and after each dose increase 2

Surgery and procedures:

• Inform all healthcare providers you are taking tirzepatide before any surgery or procedure requiring anesthesia
• Tirzepatide slows gastric emptying, increasing aspiration risk 2

Hypoglycemia risk:

• Low when used alone, but increases when combined with insulin or sulfonylureas
• Learn to recognize symptoms: shakiness, sweating, rapid heartbeat, confusion
• Carry fast-acting carbohydrates if on combination therapy 1

Lifestyle Recommendations

Essential for optimal outcomes:

• Continue healthy eating patterns - medication works best with reduced calorie intake 3
• Maintain regular physical activity
• Monitor blood glucose as directed by provider
• Attend regular follow-up appointments for monitoring 3

Monitoring Requirements

• Regular HbA1c checks (typically every 3 months initially)
• Blood glucose monitoring frequency as directed
• Kidney function monitoring, especially if experiencing persistent GI symptoms
• Weight and blood pressure tracking
• Report any vision changes if history of diabetic retinopathy 2

Key Safety Points

Gallbladder disease risk:

• Tirzepatide increases risk of gallbladder and biliary disease 3
• Report right upper abdominal pain, especially after fatty meals

Dehydration prevention:

• Critical given GI side effects
• Maintain adequate fluid intake
• Seek medical attention if unable to keep fluids down 2

Drug interactions:

• May delay absorption of oral medications due to delayed gastric emptying
• Discuss timing of other medications with provider 2